-
公开(公告)号：US20210164996A1
公开(公告)日：2021-06-03
申请号：US17046473
申请日：2019-04-12
Applicant: KONINKLIJKE PHILIPS N.V.
Inventor： Gerben KOOIJMAN , Amir Hussein RMAILE , Carl GLASSE , Marinus Karel Johannes DE JAGER , Iain Leslie Campbell CHAPPLE , Melissa Mackay GRANT , Philip PRESHAW , John J TAYLOR , Michael Alex VAN HARTSKAMP
IPC: G01N33/68
Abstract: Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and at least one of Profilin and S100 calcium-binding protein A9 (S100A9). Another combination is Pyruvate Kinase (PK) and S100 calcium-binding protein A8 (S100A8). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for absence of periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for periodontitis in said patient.
-
公开(公告)号：US20210164995A1
公开(公告)日：2021-06-03
申请号：US17046397
申请日：2019-04-10
Applicant: KONINKLIJKE PHILIPS N.V.
Inventor： Gerben KOOIJMAN , Amir Hussein RMAILE , Carl GLASSE , Marinus Karel Johannes DE JAGER , Iain Leslie Campbell CHAPPLE , Melissa Mackay GRANT , Philip PRESHAW , John TAYLOR , Michael Alex VAN HARTSKAMP
IPC: G01N33/68
Abstract: Disclosed is an in vitro method for assessing whether a human patient has gingivitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from gingivitis, the concentrations are measured of the certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and S100 calcium-binding protein A8 (S100A8), and at least one of Hemoglobin subunit beta (Hb-beta), Keratin 4 (K-4) and Pyruvate Kinase (PK). Another combination is Alpha-1-acid glycoprotein (A1AGP), Hemoglobin subunit beta (Hb-beta) and Keratin 4 (K-4). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with gingivitis. The comparison allows assessing whether the testing value is indicative of the presence of gingivitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for absence of gingivitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for gingivitis in said patient.
-
Patent Agency Ranking
公开(公告)号：US20210109113A1
公开(公告)日：2021-04-15
申请号：US17046430
申请日：2019-04-11
Applicant: KONINKLIJKE PHILIPS N.V.
Inventor： Gerben KOOIJMAN , Amir Hussein RMAILE , Carl GLASSE , Marinus Karel Johannes DE JAGER , Iain Leslie Campbell CHAPPLE , Melissa Mackay GRANT , Philip PRESHAW , John J. TAYLOR , Michael Alex VAN HARTSKAMP
IPC: G01N33/68 , G01N33/573 , G16H50/20 , G16H50/30
Abstract: Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of two or more of the proteins Matrix metalloproteinase-8 (MMP-8), Matrix metalloproteinase-9 (MMP-9), Pyruvate Kinase (PK) and S100 calcium-binding protein A8 (S100A8). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for absence of periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for periodontitis in said patient.
-
公开(公告)号：US20200368138A1
公开(公告)日：2020-11-26
申请号：US16496462
申请日：2018-03-23
Applicant: KONINKLIJKE PHILIPS N.V.
Abstract: Disclosed is a system and method for the delivery, into interdental spaces, of oral care active agents contained in particles. The particles are made of one or more superabsorbent polymers (SAP), and are of size generally small enough to be easily applied into an interdental space. To this end, the particles typically have a length of below 1.5 mm. By virtue of the SAP's ability of absorbing several times its own weight in water, the particles will swell once in contact with saliva. As a result, the volume of the particles as applied in between teeth increases by at least eight times, thereby effectively making the particles larger than the average interdental gap size. The particles, once swollen, are thus held more firmly between the walls of the interdental space, thus preventing them from being easily washed away.
-
公开(公告)号：US20210382069A1
公开(公告)日：2021-12-09
申请号：US17045312
申请日：2019-04-02
Applicant: KONINKLIJKE PHILIPS N.V.
Inventor： Gerben KOOIJMAN , Amir Hussein RMAILE , Carl GLASSE , Marinus Karel Johannes DE JAGER , Iain Leslie Campbell CHAPPLE , Melissa Mackay GRANT , Philip PRESHAW , John J TAYLOR , Michael Alex VAN HARTSKAMP
Abstract: Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of three bio marker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least two of Haemoglobin-beta (Hb-beta), Haemoglobin-delta (Hb-delta), S100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in said patient.
-
6.发明申请公开(公告)号：US20210164994A1
公开(公告)日：2021-06-03
申请号：US17045344
申请日：2019-04-02
Applicant: KONINKLIJKE PHILIPS N.V.
Inventor： Gerben KOOIJMAN , Michael Alex VAN HARTSKAMP , Amir Hussein RMAILE , Carl GLASSE , Philip PRESHAW , John TAYLOR , Iain Leslie Campbell CHAPPLE , Melissa Mackay GRANT , Marinus Karel Johannes DE JAGER
IPC: G01N33/68
Abstract: Disclosed is an in vitro method for assessing or predicting the response of a human patient to treatment of periodontal disease. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva of a patient, the concentrations are measured of certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and at least one of Interleukin-1-beta (I-1β) and 5 Matrix metalloproteinase-8 (MMP-8). Based on the concentrations as measured, at least one value is determined reflecting the joint concentrations for said proteins. This at least one value may indicate the probability that human patient has been or will be successfully treated for the periodontitis. The at least one value can be compared with at least one threshold value reflecting in the same manner the joint concentrations associated with successful treatment of 10 periodontitis. The comparison allows assessing whether the testing value is indicative of the periodontal treatment status in said patient.
-
7.发明申请公开(公告)号：US20210132083A1
公开(公告)日：2021-05-06
申请号：US17046361
申请日：2019-04-10
Applicant: KONINKLIJKE PHILIPS N.V.
Inventor： Gerben KOOIJMAN , Michael Alex VAN HARTSKAMP , Amir Hussein RMAILE , Carl GLASSE , Marinus Karel Johannes DE JAGER , Philip PRESHAW , John TAYLOR , Iain Leslie Campbell CHAPPLE , Melissa Mackay GRANT
IPC: G01N33/68
Abstract: Disclosed is an in vitro method for assessing or predicting the response of a human patient to treatment of periodontal disease. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva of a patient, the concentrations are measured of certain protein combinations. One such combination is Hemoglobin subunit delta (Hb-delta) and Pyruvate kinase (PK). Another such combination is Keratin-4 (K-4) and at least two of Alpha-1-acid glycoprotein (A1AGP), Pyruvate Kinase (PK) and Matrix metalloproteinase-8 (MMP-8). A third combination is Alpha-1-acid glycoprotein (A1AGP), Pyruvate Kinase (PK) and S100 calcium binding protein A8 (S100A8). Based on the concentrations as measured, at least one value is determined reflecting the joint concentrations for said proteins. This at least one value may indicate the probability that human patient has been or will be successfully treated for the periodontitis. The at least one value can be compared with at least one threshold value reflecting in the same manner the joint concentrations associated with successful treatment of periodontitis. The comparison allows assessing whether the testing value is indicative of the periodontal treatment status in said patient.
-
-
-
-
-
-
Search Results
7
records
(took 0.014 seconds)
